<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1055">
  <stage>Registered</stage>
  <submitdate>3/02/2006</submitdate>
  <approvaldate>3/02/2006</approvaldate>
  <nctid>NCT00287196</nctid>
  <trial_identification>
    <studytitle>Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes</studytitle>
    <scientifictitle>Randomised Clinical Trial of Surgery Versus Surgery Plus Adjuvant Radiotherapy for Regional Control in Patients With Completely Resected Macroscopic Nodal Metastatic Melanoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NHMRC 251732</secondaryid>
    <secondaryid>TROG 02.01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Malignant Melanoma</healthcondition>
    <healthcondition>Lymph Node Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: other - Radiotherapy

Active Comparator: Post-operative RADIOTHERAPY - Immediate post-operative RADIOTHERAPY

Experimental: Delayed Radiotherapy - OBSERVATION with delayed radiotherapy for relapse


Treatment: other: Radiotherapy
48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Locoregional control</outcome>
      <timepoint>Final analysis will occur when all patients have had 1 year follow up. (approx. 7 years after start of trial)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease-free survival</outcome>
      <timepoint>Final analysis will occur when all patients have had 1 year follow up. (approx. 7 years after start of trial)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Final analysis will occur when all patients have had 1 year follow up. (approx. 7 years after start of trial)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint>Interim analysis will occur on annual basis.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>Final analysis will occur when all patients have had 1 year follow up. (approx. 7 years after start of trial)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Regional macroscopic nodal metastatic melanoma in one nodal basin region only which
             has been completely resected.

          -  melanoma involving lymph nodes at high risk of local recurrence (details in protocol)

          -  No evidence of metastases

          -  No active major cancer within 5 years

          -  Normal blood tests

          -  WHO performance status of 0 or 1

          -  Radiotherapy must be able to be commenced within 12 weeks of lymphadenectomy

          -  Patient must not be pregnant and if fertile must use a medically acceptable
             contraceptive throughout treatment

          -  No major concurrent illnesses likely to cause death within 2 years

          -  Written informed consent has been given</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Evidence of active or previous local recurrence or in transit disease

          -  Evidence of distant metastases on clinical or radiological investigation

          -  Patients with prior cancers</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>250</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Mater Hospital - North sydney - Crows Nest</hospital>
    <hospital>Calvary Mater Newcastle - Newcastle</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Westmead Hospital - Wentworthville</hospital>
    <hospital>Princess Alexandra Hospital - Brisbane</hospital>
    <hospital>Royal Brisbane Hospital - Herston</hospital>
    <hospital>Mater QRI - South Brisbane</hospital>
    <hospital>East Coast Cancer Centre - Tugun</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Launceston General Hospital - Launceston</hospital>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <hospital>Andrew Love Cancer Care Centre, Geelong Hospital - Geelong</hospital>
    <hospital>Alfred Hospital - Prahran</hospital>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>1585 - Crows Nest</postcode>
    <postcode>2298 - Newcastle</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2145 - Wentworthville</postcode>
    <postcode>4102 - Brisbane</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>4224 - Tugun</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>7250 - Launceston</postcode>
    <postcode>8006 - East Melbourne</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3181 - Prahran</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Trans-Tasman Radiation Oncology Group (TROG)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University Medical Center Groningen</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australian and New Zealand Intensive Care Society Clinical Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial seeks to establish the role of post-operative radiotherapy in patients who have
      had surgery for melanoma involving lymph nodes and who are at high risk of recurrence.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00287196</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bryan Burmeister</name>
      <address>Princess Alexandra Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>